Oncology Tools

Advance your early stage in vitro discovery with a deep understanding of your novel drug candidate. In vivo pharmacology and efficacy testing that employs translational oncology tools have been shown to dramatically increase the efficiency of lead candidate selection by providing earlier and more highly predictive data.

Final read-outs of in vivo efficacy tests are especially important with immuno-oncology agents. These include not only tumor volume and tolerability data, but also changes in the immune system triggered by the test agents which are the basis of tumor inhibition and are assessed by flow cytometry, immunohistochemistry and other analyses.

Oncology Tools to Assess Biomarkers

  • Plasma biomarkers
    • Multiplex analysis of cytokines, etc. (Luminex®)
    • Flow cytometry
    • CBC/blood chemistry
  • Tissue biomarkers
    • Routine/specialized necropsy
    • Histology and immunohistochemistry
    • Western blot
    • ELISA
    • Multiplex assays (Luminex)
    • DNA and RNA isolation
    • Gene expression analysis (e.g., NanoString)

 

In Vitro and In Vivo Oncology Tools

 

Bioinformatics and genetic/RNA seq data can add significant value to your drug development.

Bioinformatics

Search for specific molecular properties and select the most relevant in vivo model using our range of bioinformatic services and our cancer model database. The database provides a range of model data such as whole exome sequencing (WES) and RNA-Seq datasets and has multi-parameter search options for all tumor model types.

 

Cytokine and chemokine protein analysis provides information on efficacy and mechanism of action.

Cytokine and Chemokine Analysis

Detecting peptides and proteins, ELISA ((enzyme-linked immunosorbent assay) supports the analysis of cytokines and chemokines in our models. Use these assays to determine in vivo efficacy and mechanism of action.

 

Flow cytometry allows identification of cell populations, allowing analysis of immune regulation of cancer treatments.

Flow Cytometry

Achieve a comprehensive analysis of the immune system with our in-house multiplex flow cytometry. Identification of various cell populations supports a deep interrogation of the immune response elicited from novel therapeutics. Our streamlined process for tissue dissociation, cell isolation, staining and acquisition, systemic and tumor-infiltrating immune cells allows you to review the data and make quick decisions about compounds and studies.

 

Gene expression analysis provides information on changes in tumor growth and mechanism of action.

Gene Expression Analysis

Identify the genetic changes that correlate to immune-driven changes in tumor growth using gene expression analysis. Used in preclinical pharmacodynamic studies, this tool delivers evidence of mechanism of action for novel immune-oncology therapies. For example, our tumor-infiltrating lymphocyte (TIL) assay uses RNA isolated from snap-frozen tumor sections to analyze differential gene expression, providing insight into the type and quality of the immune response generated.

 

In Vivo Imaging

From examining biodistribution of antibodies or immune cells in tumor-bearing animals to quantifying cancer-related biomarkers, our validated 2D and 3D in vivo optical imaging of oncology endpoints has many applications. Used to optimize dose and delivery strategies, imaging data ultimately improves your therapy’s translation to the clinic.

 

Gene expression analysis provides information on changes in tumor growth and mechanism of action.

Live Cell Imaging

Collect real-time data on mechanism of action with live cell imaging techniques such as IncuCyte®. This valuable tool greatly enhances in vitro oncology and immuno-oncology assays.

 

Pathology, histology and immuno-histochemistry provides additional data for in vivo oncology models.

Pathology, Histology & Immunohistochemistry (IHC)

Pathology, histology and IHC techniques are essential oncology tools that add significant data to in vivo oncology models. This information is particularly useful for your PDX studies, as these models preserve tumor architecture with a heterogenous cell content.

 

Radiation can be used as a therapeutic regimen in oncology, or as a research tool to study the harmful effects.

Radiation

Irradiation of in vivo and in vitro biological systems can be used both as a therapeutic regimen to evaluate effects on tumor growth and as a research tool to study the harmful effects of radiation on these systems.

 

In vivo microdialysis is a uniquely sensitive, powerful method of sampling the tumor microenvironment in murine models.

Tumor Microdialysis

Uniquely sensitive and powerful, in vivo microdialysis is a method of sampling the tumor microenvironment in murine models, allowing you to effectively monitor changes in the biochemistry of tumors. The data derived from these studies is essential to our understanding of cancer biology and our ability to develop novel cancer therapies. With oncology tools like this, we can detect and quantify multiple immunomodulators and oncometabolites, elucidating mechanism of action.

 

Oncology tools, ex vivo analysis, and oncology endpoints can provide much needed data to progress to this clinic.

Request more information

Frequently Asked Questions (FAQs) about Oncology Tools:

  • Which of Charles River’s oncology tools can support pharmacology studies?

    We offer a comprehensive range of oncology tools, including bioinformatics, protein expression, gene expression, flow cytometry, pathology, IHC, in vivo and in vitro imaging, and tumor microdialysis. Monitoring the right oncology endpoints using these tools can add significant value to in vivo and in vitro pharmacology models.

  • How can bioinformatics add value to my oncology study?

    Oncology tools such as bioinformatics can significantly enhance your study dataset by with the analysis of important oncology endpoints; genetic, RNA and protein expression data can predict the best model for your research and provide information on efficacy and mechanism of action. You can find a range of publications from our partners here.